Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | UPP1 | Q16831 | 3/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884023 | 0.89 | KDM4E (0.36) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL21425811 | 0.88 | KDM4E (0.39) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL23638562 | 0.86 | KDM4E (0.37) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL23638559 | 0.86 | KDM4E (0.37) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL4632645 | 0.84 | ALDH1A1 (0.44) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL23638823 | 0.82 | KDM4E (0.39) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL23031757 | 0.79 | KDM4E (0.40) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL23638802 | 0.78 | KDM4E (0.36) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL22736981 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL13387595 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170256720-A1 | ORGANIC LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING MATERIAL AND COMPOUND USED THEREFOR | KYULUX, INC. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9502668-B2 | Organic light-emitting device, and light-emitting material and compound used therefor | KYULUX, INC. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150105564-A1 | ORGANIC LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING MATERIAL AND COMPOUND USED THEREFOR | KYULUX, INC. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170256720-A1 | ORGANIC LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING MATERIAL AND COMPOUND USED THEREFOR | CRY1, WEE1, OR51E2 | KDM4E 3233/4885ALDH1A1 80/4885MEN1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.